Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celastrol is a pentacyclic triterpenoid compound isolated from the root extracts of Tripterygium wilfordii (Thunder God Vine), a traditional Chinese medicinal plant[1][2][6]. It exhibits potent anti-inflammatory, antioxidant, and anticancer activities. Celastrol has demonstrated neuroprotective effects in preclinical models of memory impairment and neurodegenerative diseases by reducing oxidative stress and attenuating neuroinflammation[1][2]. Its mechanisms include modulation of multiple cell signaling pathways such as NF-κB, MAPK, JAK/STAT, PI3K/Akt/mTOR pathways; inhibition of angiogenesis via VEGFR suppression; regulation of apoptosis and proteasome activity; stimulation of heat-shock protein response; immunomodulation; and leptin sensitization for potential obesity treatment[2][6]. Celastrol is being explored as a lead molecule for drug development targeting chronic inflammatory diseases (e.g., rheumatoid arthritis), autoimmune disorders (e.g., systemic lupus erythematosus), neurodegenerative conditions (e.g., Alzheimer's disease), cancer, obesity/metabolic syndrome, type 2 diabetes mellitus and more[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celastrol.